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Abstract – Notwithstanding technological 
improvements in endovascular devices treatment of 
steno-obstructive lesions of the superficial femoral 
artery (SFA) remains a challenge for today’s vascular 
surgeon. Current opinion dictates that the diabetic 
population may have worse outcome after 
revascularization of the lower extremities. Herein we 
examine the effects of endovascular treatment on 
steno-obstructive lesions of the SFA in diabetic and 
non-diabetic patients.  
Methods – A retrospective analysis was carried out on 
110 patients who had undergone endovascular 
treatment of the SFA from 2010 to 2017 comparing 
outcomes in diabetic (DM) vs non-diabetic patients 
(nDM).  
Results – 56 (50.9%) of the patients were diabetic and 
54 were non-diabetic (49.1%).  52.7% (62.7% DM vs 
35.2% nDM, p = 0.0003) were patients with critical 
limb ischemia. SFA occlusion was present in 65.5% 
(60.7% DM vs 70.4% nDM, p = 0.29) of all patients. 
All had undergone PTA of the SFA and 40.9% had 
received adjunctive stenting (44.6% DM vs 37.0% 
nDM, p = 0.41). A multilevel treatment was executed 
in 39.1% (51.8% DM vs 25.9% nDM) of the cases 
whereas an infra-popliteal procedure was associated 
in 27.3% (37.5% DM vs 16.7% nDM). In both groups 
the presence of diabetes was significantly associated 
(p = 0.005 e p = 0.014, respectively). Reintervention 
rate was 22.7%; 13 in the diabetic group (23.2%) and 
12 in the non-diabetic group (22.2%). Of those who 
had had reintervention (p = 0.77); 9 patients (8.2%) 
had undergone an open surgical operation, 6 of whom 
had diabetes (p = 0.32). 5 patients (4.5%) had had 
major amputation, 4 of whom were diabetic (p = 
0.20). Curves assessing freedom from target lesion 
restenosis were substantially overlapping between the 
two groups.  
Conclusion - No statistical associations between 
diabetes and reintervention or amputation rates were 
found. Indication to treat the SFA were not influenced 
by the presence of diabetes but further investigation is 
required to verify our hypothesis. 
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I.  INTRODUCTION 
 
The superficial femoral artery (SFA) still today 
remains a great challenge for the Vascular Surgeon. 
Over the last few years’ innovations and technological 
developments in the endovascular field such as drug 
coated or atherectomy devices1, interwoven stents, 
intravascular lithotripsy, etc., have certainly 
increased. Despite this, long-term outcomes are not 
fully satisfactory. A recent series shows a patency rate 
of 51% at 3 years after percutaneous intraluminal 
angioplasty (PTA) and provisional stenting of the 
SFA.2 The presence of complex lesions (TASC II D) 
negatively affects the results with primary patency 
rates of 60.1% at 1 year, 50.6% at 3 years and limb 
salvage rates of 63.7% at 4 years.3 Even the use of 
drug coated devices does not seem to improve these 
data; a single-centre study shows patency rates of 56% 
and 39% at 1 and 2 years, respectively.4 The reasons 
for this poor success have been ascribed to the 
anatomic peculiarities of the SFA which is prone to 
deformations such as kinking, twisting and external 
compression during the flexion-extension movements 
of the knee. These forces may be responsible for 
restenosis following endovascular procedure.5-6 
Moreover, the highly calcified nature of the 
atherosclerosis plaques in the femoropopliteal 
segment is well known and seems to be correlated to 
a young-age medial tunica calcinosis.7 Several studies 
show that patency after endovascular intervention is 
linked to degree of calcification.8-9 
 Diabetic patients are well known for the severity and 
precocity of peripheral arterial disease (PAD) with a 
major risk of amputation. This is due to significant 
changes in the composition and function of the arterial 
wall caused by a dysmetabolic state10-11 and also for 
the peripheral neuropathy and local susceptibility to 
infections. In fact, amongst diabetic patients PAD has 
unique features such as early age onset, simultaneous 
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arteriopathy in other segments, aggressive 
progression, high incidence of calcified lesions, distal 
and microcirculatory involvement and reduced 
collateral reserve.12-13 This becomes even more 
relevant if we consider that diabetes mellitus not only 
represents a highly invalidating disorder with terrible 
complications, but also the fact that its worldwide 
diffusion continues to increase with a global 
prevalence  expected to rise to 552 million by 2030. 14 
Endovascular treatment has a growing application 
among diabetics who are often not eligible for open 
surgery due to the absence of distal target vessels for 
a peripheral bypass and the coexistence of several 
comorbidities and poor general conditions.15-16 
However, diabetic patients show diminished primary 
patency rates after endovascular revascularization of 
the lower extremities.17 These data are even worse in 
cases of poor perioperative glycaemic control.18 In 
addition, a failed endovascular treatment could have a 
negative impact on the success of a potential 
subsequent bypass19 given the frequent lack of run-off 
vessels among diabetic patients. For these reasons an 
endovascular approach to this challenging segment of 
diabetic patients could be presumed to have poor 
success but in reality the data in the literature is not 
univocal.  
The aim of this study is to examine a population of 
patients with PAD who had undergone endovascular 
treatment of SFA and compare the outcomes between 




A retrospective analysis on 110 patients with PAD 
who had undergone endovascular treatment on SFA 
was conducted. The study included patients admitted 
to a tertiary referral academic hospital from January 
2010 and December 2017. Patients who had 
experienced 1) claudication with mean walking 
distance < 200 meters not responsive to medical 
therapy and daily exercise, 2) resting pain and 3) ulcer 
or necrosis of lower extremities were all included. All 
patients presented with atherosclerosis lesions of the 
SFA, with or without the involvement of other arteries 
of the same limb.  
The decision to treat patients with an endovascular 
procedure of the SFA as first line was based on 
clinical examination and lesion morphology assay. 
Before surgery, diagnostic evaluations 
comprehensive of lab tests, two view chest 
radiographs, cardiologic and anesthesiological 
assessments were carried out. A clinical and 
hemodynamic examination of the lower limbs 
comprehensive of the Ankle-Brachial Index (ABI), 
was also made. The presence of values < 0.40 was 
established as indication of severe peripheral 
vasculopathy. A measure of pre- and post-procedural 
Transcutaneous Oximetry (TcPO2) was realized on 
most patients with trophic lesions. 
A preoperative Computed Tomography Angiography 
(CTA) was given to most patients to investigate 
arterial lesions:  differentiation between stenosis and 
obstruction, length of lesions, presence of highly 
calcified plaques and the conditions of run-in and run-
off vessels were all examined. These aspects played 
an essential role in indication to treat. In other cases, 
a lower extremities Arteriography made at the same 
time as treatment. 
The endovascular procedures were performed in the 
Operatory Room or in the Interventional Radiology 
Room. Patients with chronic kidney disease 
underwent pre- and post-operative hydration. Local 
anesthesia with sedation was administered to almost 
all patients. In a minority of cases general or 
subarachnoid anesthesia was administered. Access to 
the SFA was most frequently obtained with a 
retrograde ultrasound-guided puncture of the 
contralateral common femoral artery (CFA) and 
crossover approach. In selected cases an anterograde 
puncture of the CFA or a left brachial artery access 
was achieved. In only one case a retrograde puncture 
of the anterior tibial artery was associated with 
traditional access. In most cases a PTA of the 
atherosclerosis lesion was realized after injection of 
iodinated contrast media. Different devices were 
chosen, depending on the attending physician’s 
preference and of an appropriate size and length 
according to the anatomy of the lesions (range 4-7 mm 
and 20-220 mm, respectively).  Duration of dilation 
varied between 1 and 2 minutes.  
Stent deployment was more often utilized as “rescue 
therapy” in cases of unsatisfactory PTA results 
(residual stenosis > 30% or re-stenosis) or of flow 
limiting flap / dissection. Primary stent placement was 
preferred in the presence of long chronic total 
occlusion of the SFA. In other cases, the choice of 
device fell to drug coated balloons and/or atherectomy 
in the presence of highly calcified lesions when stent 
positioning was not recommended or not considered 
by preference of the physician.  
In some cases, treatment of the SFA was associated 
with an open-surgery or endovascular treatment on 
other arteries of the same limb consisting of 
endarterectomy of the CFA +/- profundoplasty, iliac 
PTA +/- stenting, or PTA of the popliteal or tibial 
arteries. Adjunct procedures were meant to improve 
the SFA inflow or outflow and were considered based 
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upon the presence of trophic lesions, patient’s general 
conditions and lifestyle. 
In this study patients with acute-on-chronic ischemia 
caused by plaque thrombosis were also included. In 
such conditions loco-regional fibrinolysis, aspiration 
thrombectomy and/or sodium heparin injection were 
initially performed. 
During the post-operative period antiplatelet therapy 
and, in cases of stenting, double antiplatelet drugs 
were administered for 6 months. 
Diabetes mellitus was defined based upon blood 
glucose level measurement and confirmed by 
antidiabetic drug consumption (Oral Hypoglycemic 
Agents and/or insulin). In 8 patients presence of 
diabetes mellitus was discovered during 
hospitalization for treatment of PAD. Presence of 
arterial hypertension was assessed by arterial pressure 
measurement and antihypertensive drugs. 
Dyslipidemia was defined on the basis of lab tests 
and/or antilipemic drug consumption. Chronic kidney 
disease was defined by presence of creatinine blood 
level > 1.5 mg/dL and/or dialyze. Coronaropathy was 
considered in relation to anamnestic history of 
coronary artery revascularization. 
Before hospital discharge, peripheral pulse 
examination, ABI measurement, pain-free walking 
distance and resting pain evaluation were all 
evaluated. Trophic lesions were assessed in the long 
term through outpatient medications. Our study 
considered post-operative ABI increasing by more 
than 0.10 as significant. Patients had undergone 
duplex follow up at 1-3-6-12 months after procedure. 
Target lesion patency, measure of restenosis or 
residual stenosis and downstream flow were 
evaluated. Hemodynamically significant stenosis was 
defined by a PSV ratio > 2.5 between upstream and 
downstream PSV in relation to target lesion.  
Medium follow-up was 17.9 months (range 0-96.4). 
Procedure related mortality was 3.6% (3.6% DM vs 
3.7% nDM)         
Primary endpoints were hemodynamic improvement, 
the presence of hemodynamically significant 
restenosis or re-occlusion of target lesion, 
endovascular or open-surgery reintervention in the 
femoro-popliteal segment and limb salvage. 
Exclusion criteria were procedure failure, previous 
endovascular or open-surgery procedures on the SFA 
and cases of intrastent restenosis treatment. 
All data are reported as numeric values or 
percentages. Chi-square analysis and the Fisher test 
were used to evaluate differences between diabetic 
and non-diabetics patients. All values of p < .05 were 
considered statistically significant. The analysis of 
freedom from hemodynamical restenosis of target 




Total number of patients in the study were 110 of 




Average age was 69.4 years in the DM group vs 70.9 
years in the nDM group. All data for DM, nDM and 
total number of patients are given in Figure 1. A 
statistically significant association was found between 
diabetes and the presence of dyslipidemia (71.4% DM 
vs 51.9% nDM, p = 0.035) and coronaropathy (37.5% 
DM vs 23.5% nDM, p = 0.014). Surprisingly, a 
history of smoking was more frequent in the nDM 
group, with a significant relationship (60.7% DM vs 
85.2% nDM, p = 0.024). 52 patients suffered from 
claudication and 58 from critical limb ischemia (CLI). 
As expected, a statistically significant relationship 
was found between diabetes and CLI (67.2% DM vs 
35.2% nDM, p = 0.0003). ABI showed values 
consistent with severe PAD (<0.40) in 46.4% of DM 
vs 40.7% of nDM, although without a strong 
relationship (p = 0.79). 
 
 
Figure 1.  Demographics and clinical data. 
 
Lesion characteristics 
In 72 patients (65.5%) preoperative imaging showed 
an SFA occlusion, particularly in 60.7% of the DM 
and 70.4% of the nDM (p = 0.29) group. The mean 
length of occlusion was 9.4 cm (range 1-30 cm); 8.6 
cm (range 1-25 cm) in the DM group and 10.2 cm 
(range 2-30 cm) in the nDM group. The mean lesion 
length in general (stenotic and obstructive together) 
was 10.9 cm (range 1-30 cm); 10.6 cm (range 1-30 
cm) in the DM group and 11.2 cm (range 2-30 cm) in 
the nDM group.  
 
In 37 patients (33.6%) the proximal third of SFA was 
involved (25.0% DM vs 42.6% nDM) with a near-
significant trend (p = 0.051). Out of this group   
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patients with unique short lesions at the origin of the 
SFA with femoral bifurcation involvement were 
excluded; in those patients a femoral endarterectomy 
was offered. Conversely, in 59 patients (53.6%) the 
level of lesion was the distal third of the SFA (62.5% 
DM vs 46.3% nDM, p = 0.13). Patients with continual 
involvement of the supragenicular popliteal artery 
were included with the exception of those with isolate 
popliteal lesions. (Figure 2) 
Preoperative tibial run-off defined as number of 
patent tibial vessels to the foot was assessed. 23 
patients had only one patent vessel and 11 patients had 
an absence of run-off tibial arteries accounting for 34 
patients (30.9%) considered to have poor run-off. 
33.9% of the DM group and 27.8% of the nDM group 
had only ≤ 1 run-off vessels (p = 0.49).  
 
 
Figure 2. Characteristics of lesions and treatment 
 
Treatment 
All patients received PTA of SFA. In 13 patients a 
drug coated balloon was employed. Interestingly, 
only one of these was diabetic with a statistically 
significant relationship (p = 0.0008). In 9 cases the 
artery was preoperatively occluded. In 6 patients an 
atherectomy was also carried out, 2 in the diabetic 
patients. In 45 patients (40.9%) stent placing was 
associated to PTA. Of these, 25 patients were diabetic 
and 20 non- diabetic (44.6% DM vs 37.0% nDM, p = 
0.41). In 36 cases there was a preoperative obstruction 
of the SFA. Only nitinol self-expandable stents were 
positioned, almost all uncovered. In 3 cases (n. 2 DM) 
a covered stent was released. The mean diameter of 
stent was 5.9 mm (range 5-7 mm). In most cases only 
one device was placed/inserted. In 7 patients 2 stents 
were released (n. 4 DM) and in 2 patients 3 stents (n. 
1 DM) were released. No drug eluting stents were 
placed. 
In 43 patients (39.1%) a multivessel treatment was 
performed (51.8% DM vs 25.9% nDM) with this 
association being statistically significant (p = 0.005). 
13 patients were offered an adjunctive iliac or femoral 
procedure (8 DM vs 5 nDM), otherwise 30 patients 
received an adjunctive infragenicular popliteal and/or 
tibial procedure (21 DM vs 9 nDM) with statistical 
significance (p = 0.014).       
 
Follow up 
Kaplan-Meier curves for freedom from 
hemodynamical restenosis of target lesions for 
diabetics and non-diabetics were formulated. (Figure 
3). The curves were substantially overlapping 
between the two groups; a log rank test showed 
absence of a significant relationship (p = 0.91). One 
month after procedure, freedom from restenosis was 
major in the DM group (91.7% DM vs 83.7% nDM, p 
= 0.23). After 6 months this trend inverted (72.9% 
DM vs 75.5% nDM, p = 0.77). Even in the long term, 
freedom from restenosis rates were substantially 
similar between the two groups with a slightly worse 
trend among diabetics: 62.5% DM vs 73.5% nDM (p 
= 0.25), 54.2% DM vs 57.1% nDM (p = 0.77), 45.8% 
DM vs 53.1% nDM (p = 0.41) at 1, 2 and 5 years, 
respectively. An increase of ABI > 0.10 on the first 
postoperative day was present in 83.6% (80.4% DM 
vs 87.0% nDM, p = 0.34). In 36 patients values of 
TcPO2 increased from 12.3 +/- 7.1 to 39.3 +/- 11.6.  
 
 
Figure 3. Kaplan-Meier curves for freedom from restenosis 
at 5 years for diabetics (DM) and non-diabetics (nDM) 
 
During the entire follow up rates of total 
reinterventions on target lesions, open surgical 
reinterventions and lower limb amputations were 
22.7% (23.2% DM vs 22.2% nDM, P = 0.77), 8.2% 
(10.7% DM vs 5.6% nDM, P = 0.49) e 4.5% (7.1% 
DM vs 1.9% nDM, P = 0.36), respectively and no 
statistically significant differences were found. In 
cases of endovascular reintervention, a re-PTA, with 
or without stenting, was executed. In the presence of 
intrastent thrombosis this procedure was preceded by 
loco-regional fibrinolysis. In cases of open surgical 
conversion, a femoro-popliteal bypass, above or 
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below the knee, was realized in almost all of the 
patients.  In only one case a profundoplasty with patch 
enlargement was done. 
Also amongst the claudicants any statistical 
association was found between diabetes and 
reintervention rate or open surgical operation (p = 
0.96 and 0.31, respectively). Major amputation rate 
was 0%. (Figure 4). 
 
Figure 4. Hemodynamical improvement, reintervention 





In the present study no statistically significant 
differences in the outcome of SFA revascularization 
between the diabetic and non-diabetic patients were 
found although the trend was slightly worse in the DM 
group. A supposition of the main reason for this could 
be in the combination of patient characteristics and 
lesions for which endovascular treatment was initially 
recommended. Endovascular treatment was preferred 
in cases of anatomic lesions which, from our point of 
view, could have benefited.  The same procedure was 
also performed in patients considered unfit for 
surgery. For patients with more complex lesions a 
femoral-popliteal bypass was chosen as first choice 
however these latter are not considered in the current 
study. 
Darling et al. made a comparison between an 
“endovascular first” vs “bypass first” strategy on a 
femoral popliteal segment in patients with insulin 
dependent diabetes with CLI; “bypass first” patients 
had significantly lower unadjusted 6-month rates of 
incomplete wound healing (49% vs 57%) and 5-year 
rates of restenosis (53% vs 72%) and reintervention 
(47% vs 58%; all P < .05)., with perioperative 
complications not differing.20 
In our study, rates of total reinterventions (22.7%), 
open surgical reinterventions (8.2%) and major 
amputations (4.5%) are comparable to the data in the 
literature. Amputation rates of 5% are reported by 
other authors21 and another study shows limb-salvage 
rates of 90% at 24 months.22 Shammas et al. reported 
a reintervention rate of 17% at 2 months.23 Data 
concerning freedom from restenosis are also 
comparable to the literature, with rates of 62-79% and 
37-55% at 1 and 5 years, respectively.24 
In a study of 1075 endovascular procedures on SFA 
with mean follow up time of 34 months, Abularrage 
et al. found rates of 5-year primary patency (PP) and 
limb salvage significantly worse amongst diabetics 
(37% vs 46% P = 0.009 and 84% vs 93% P = 0.0001, 
respectively) despite the fact that the assisted patency 
(PA) was did not differ. The authors concluded that 
diabetes is an independent predictor of decreased 
long-term PP and that strict surveillance could 
improve the PA.25 A previous study of the same group 
with mean follow up time of 24 months did not show 
significant differences between the two populations.26 
The explanation of the authors for this is the reduced 
period of post-operative surveillance. In our study the 
curves for freedom from hemodynamical restenosis 
substantially overlap between the two groups, with 
even better results amongst diabetics during the first 6 
months. These data support the hypothesis that 
diabetes could have a negative impact, especially on 
long-term outcomes of these procedures, but further 
studies are needed. 
Shammas et al., in a similar study, found a significant 
relationship between diabetes and amputation at 12 
months (HR 5.02, 95% CI 1.44 to 17.56, P = 0.011) 
with increased risk among patients with CLI. 
However, no differences of reintervention rates were 
found.23 
Several studies on the efficacy of SFA endovascular 
treatment consider diabetes as predictive of patency 
failure.22, 27-29 
Bodewes et al. reported that diabetes was a predictive 
factor of 30-day unplanned hospital readmission after 
infrainguinal endovascular intervention due to non-
healing wounds, infections or recurrence of 
symptoms. The authors suggested strict surveillance 
and prophylactic measures among categories at risk.29 
Conversely, Xiao et al. reported the complete absence 
of significant differences between diabetics and non-
diabetics in terms of PP (73.2% DM vs 80.9% nDM, 
58.6% DM vs 52.8% nDM, at 1 and 3 years 
respectively) and limb salvage (81.9% DM vs 83.1% 
nDM at 3 years), showing a similar efficacy of 
endovascular treatment in these two groups.31 
In a study by Bakken et al., patients who had 
undergone endovascular procedure on SFA were 
divided into non-diabetics, non-insulin-dependent 
diabetics and insulin-dependent diabetics and were 
then separately considered in two categories: 
claudicants and CLI-affected. Among claudicants no 
significant difference in PP existed between the three 
groups, even with increased rates of PP (72% vs 51% 
at 5 years) and freedom from restenosis (68% vs 57% 
at 3 years) between the non-insulin-dependent 
diabetics and the non-diabetics. Among patients with 
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CLI, no significant differences were noted between 
the three groups in PP, PA and freedom from 
restenosis, with primary patency rates found to be 
even higher among insulin-dependent diabetics 
compared to non-diabetics (57% vs 30% at 3 years).24 
A review of Ihnat et al.  on endovascular treatment of 
the lower limb amongst diabetics concluded that 
patients who had undergo intervention for SFA 
lesions are a very heterogeneous group and further 
studies are required to understand the impact of 
diabetes on outcomes. The role of diabetes itself in 
patency and restenosis rates is probably less important 
than other factors such as TASC classification and 
tibial run-off.32 
In our experience diabetes was significantly 
associated with dyslipidemia and coronaropathy and 
inversely correlated with smoking history. This latter 
finding could be explained by the role of smoking 
prevention and discouragement campaigns which are 
displayed in our diabetic foot ambulatory Care clinic. 
On the other hand, it is likely that patients who were 
both diabetics and smokers were more frequently 
judged not eligible for endovascular treatment or 
underwent direct amputation due to the major 
complexity of arterial lesions and the worsening 
clinical conditions of limbs.  
In this study, as in others, an association between 
diabetes and CLI was found. In fact, in several articles 
the presence of CLI was a negative predictor of failure 
of SFA endovascular intervention and amputation.21,25 
Shammas et al. found an association between diabetes 
and limb loss only among patients with CLI.23 In our 
study attention was primarily focused on the role of 
diabetes itself regardless of clinical conditions of the 
lower limb. 
In the same way attention was turned to the presence 
of diabetes or not without previously considering the 
nature of arterial lesions. This may explain the 
absence of association of diabetes with length of 
lesions or presence of occlusions. More complex 
lesions did not usually receive endovascular 
procedures. In fact, there were only 9 cases of 
obstructive lesions of the SFA longer than 20 cm. In 
addition, other studies also concur with the absence of 
this association.23,25 
No association between diabetes and poor tibial run-
off was found either. This is in contrast to the presence 
of association between diabetes and CLI however the 
role of diabetic microangiopathy in the pathogenesis 
of trophic lesions should to be taken in account. 
Conversely, other studies reported a significant 
association between diabetes and poor run-off.22,24 
Eventual association between diabetes and location of 
lesions in the SFA was evaluated with a near- 
significant association (p = 0.051) with proximal SFA 
involvement. Bakken et al. found an association with 
mid tract SFA or popliteal involvement in the CLI 
subgroup.24 
Regarding to the choice of the device, an interesting 
association between absence of diabetes and use of 
DCB was found. We preferred to take advantage of 
the potential of drug coated balloons in those lesions 
which would certainly have benefitted from this. In 
cases of highly calcified lesions or those that didn’t 
respond to simple PTA, more often, like those of 
diabetics, we were most likely to use a stent. The use 
of stents was prevalent among diabetics, even in the 
absence of significance. The Belgian Diabetic 
IN.PACT Trial reported excellent results using DCB 
among diabetics,33 although another study considered 
diabetes as a predictor of late-lumen-loss after DCB 
in SFA.34 Kay et al. found a relationship between Oral 
Hypoglycemic Agents and patency failure after 
stenting of SFA but no association between insulin-
dependent diabetes and patency.21 Another study 
found diabetes to be an independent factor of patency 
loss at 6 months after stent positioning in SFA due to 
long chronic occlusions.29 The DEFINITIVE LE Trial 
reported 12-month patency rates between diabetics 
and non-diabetics similar after a directional 
atherectomy in femoral popliteal disease among 
claudicants.34  
In the present study almost all the diabetics received a 
multivessel treatment more frequently on 
infrapopliteal vessels to improve run-off. A possible 
explanation could be the major rate of CLI among 
diabetics which means that a more aggressive 
approach was managed. 
 
Limits  
The most probable bias of our conclusion is that 
patients with lesions which were considered complex 
from an endovascular point of view more often 
received a “bypass first” approach while an 
“endovascular first” treatment was chosen for patients 
with lesions which were considered more responsive, 
independently of the presence of diabetes itself. 
Therefore, the diabetic patients in our study had less 
complex lesions and endovascular procedures most 
probably had outcomes comparable to the non-
diabetics.  
Another limit is the relative shortness of the mean 
follow up time. Unfortunately, several cases of death 
during the postoperative period were recorded. Many 
of these patients had already presented clinical 
conditions at time of hospitalization. On the other 
hand, the choice of an endovascular procedure in 
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these patients was precisely dictated by their poor 
conditions. 
Measurements of quantity and distribution of 
calcifications in the SFA lesions using scores such as 
PACSS were not executed the reason being the 
unavailability of a preoperative CTA in a fair number 
of cases. In these latter patients the first preoperative 





V. CONCLUSIONS  
 
In the current study perspective was voluntarily 
altered and attention was focused on the role of 
diabetes itself rather than starting from the 
characteristics of arterial lesions or from clinical 
conditions of the limb. Our study found a substantial 
similarity of outcome between diabetics and non-
diabetics both in the short and long term. The sole 
presence of diabetes itself did not significantly 
influence the results whereas other factors like lesion 
characteristics seem to have played an important role.  
This highlights the importance of the appropriate 
selection of patients to undergo endovascular 
procedures for femoral popliteal disease. An 
“endovascular first” approach should be carefully 
examined after careful investigation of arterial 
lesions, local conditions of limbs and general status. 
Our experience tells us that patients who are judged 
not suitable for endovascular procedure should 
directly receive, when possible, an open surgical 
intervention. Proper selection could potentially lead to 
satisfactory results of endovascular treatment on SFA, 
even in diabetic patients, who are, by definition, more 
difficult to treat. Thus, it is highly desirable that new 
scores be created, to better define which patients 
could be offered an endovascular procedure on SFA. 
Moreover, further research is needed to clarify the 
role of diabetes in this field of Vascular Surgery 
particularly defining at which level and how  could 
exert its influence on outcome.             
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